Dr. Pullen believes that Pradaxa, generic name dibigatran, has the potential to change the way atrial fibrillation is managed to prevent stroke.
This article originally appeared online at Dr.Pullen.com.
Pradaxa, generic name dibigatran, has the potential to change the way we manage atrial fibrillation to prevent stroke. Stroke is one of the most feared medical problems for many patients, and atrial fibrillation is one of the biggest risk factors for stroke. Stroke is the third leading cause of death in the U.S. and the leading cause of long term disability. Having atrial fibrillation increases a person’s risk of having a stroke about five fold and is the cause of 15-20% of strokes in America, over 100,000 strokes a year. Most patients with atrial fibrillation are candidates for long-term anticoagulation, and until Pradaxa was approved by the FDA in October, 2010 patients were either treated with oral warfarin, injectable low molecular weight heparin, or with less effective anti-platelet medications like aspirin.
Warfarin has been the choice of most physicians and patients for prevention of stroke in patients with atrial fibrillation because it works well. The annual risk of stroke in patients with atrial fibrillation is 4.5% without warfarin anticoagulation, and 1.4% with warfarin treatment. This risk varies a great deal from individual to individual depending on associated risk factors like coexisting hypertension, diabetes, congestive heart failure, prior TIA or stroke and age over 75. A scoring algorithm called the CHADS2 score is often used to better assess an individual’s risk. For most patients the absolute reduction in risk of stroke is high enough that most physicians have encouraged most of their atrial fibrillation patients to take warfarin. Warfarin therapy is no small undertaking though and has very significant bleeding risks. Several major problems are involved with use of warfarin as an anticoagulant:
Pradaxa is approved by the FDA for treatment of atrial fibrillation at a single fixed dose for most patients. It is dosed at 150 mg twice daily, and is effective within hours of taking the first dose. It works at least as well as warfarin to prevent stroke in patients with non-valvular atrial fibrillation, and overall the Pradaxa side effects profile is generally lower than with warfarin. In addition Pradaxa has far fewer drug interactions than warfarin which is notoriously affected by both diet changes and innumerable other medications. Bleeding risks with Pradaxa seem to be about the same overall as with warfarin. There may be a minimally lower risk of major cerebral hemorrhage and a higher risk of gastrointestinal bleeding with Pradaxa vs. warfarin.
The big issue holding back the widespread use of Pradaxa is its cost. Pradaxa costs $230./ 60 doses (30 days) at Costco.com and remains a tier 3 drug on many insurance formularies. Still the cost of warfarin therapy is not trivial. A rough estimate of just some of the costs of warfarin therapy might include:
When the lower risk of cerebral hemorrhage complications that can often lead to very expensive hospitalizations and long term nursing home care with Pradaxa is included the overall cost may turn out to be comparable or even less for Pradaxa therapy when compared to warfarin anticoagulation. I’ll be interested to see post marketing cost analysis comparisons as they become available.
I will not be surprised if as more physicians gain experience with Pradaxa, and more cost analysis is done, that Pradaxa will become the standard of care for treatment of atrial fibrillation for stroke prevention in patients at high enough risk of stroke to warrant the risks of therapy.
Ed Pullen, MD, is a board-certified family physician practicing in Puyallup, WA. He blogs at DrPullen.com — A Medical Bog for the Informed Patient.